Two-drug treatment before surgery for clear cell kidney cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing a combination of two drugs, zanzalintinib and pembrolizumab, given before surgery to people with a specific type of kidney cancer (clear cell renal cell carcinoma) that can be removed. The goal is to see if this treatment helps shrink or control the cancer before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of kidney cancer called clear cell renal cell carcinoma that your doctor has confirmed needing surgery.
- Your cancer should be locally advanced (meaning it has spread beyond the kidney but not far) or have spots that can be completely removed with surgery.
- You must be 19 years or older and be in good enough physical condition (ECOG score 0 or 1) to undergo treatment.
- You must have at least one tumor that can be measured on scans.
- Your blood, kidney, and liver function must be within acceptable ranges.
- You must not have had prior immunotherapy (like PD-1/PD-L1 inhibitors) or targeted therapy (like VEGFR inhibitors) for your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial tests if taking two drugs, belzutifan and pembrolizumab, before surgery can help shrink high-risk kidney cancer tumors and improve outcomes. It may be an option for people with locally advanced clear cell kidney cancer who are scheduled for nephrectomy.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests a combination of two drugs, cardenilimab and lenvatinib, given before and after surgery to remove kidney cancer. The goal is to see if this approach helps prevent the cancer from coming back. It is for people with early-stage (non-spread) clear cell kidney cancer who are healthy enough for surgery.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
Hear when a new Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.